Cargando…

Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study

BACKGROUND: Data on the burden of mumps in South Africa are limited and the epidemiology of mumps in this setting is not well understood. We present an analysis of mumps data in South Africa from 2012 to 2017. METHODS: This cross-sectional study included secondary data on laboratory-confirmed mumps...

Descripción completa

Detalles Bibliográficos
Autores principales: Sikhosana, Mpho Lerato, Kuonza, Lazarus, Motaze, Nkengafac Villyen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216493/
https://www.ncbi.nlm.nih.gov/pubmed/32397991
http://dx.doi.org/10.1186/s12889-020-08835-x
_version_ 1783532421907480576
author Sikhosana, Mpho Lerato
Kuonza, Lazarus
Motaze, Nkengafac Villyen
author_facet Sikhosana, Mpho Lerato
Kuonza, Lazarus
Motaze, Nkengafac Villyen
author_sort Sikhosana, Mpho Lerato
collection PubMed
description BACKGROUND: Data on the burden of mumps in South Africa are limited and the epidemiology of mumps in this setting is not well understood. We present an analysis of mumps data in South Africa from 2012 to 2017. METHODS: This cross-sectional study included secondary data on laboratory-confirmed mumps infections from 2012 to 2017, archived at the South African National Health Laboratory Services’ data repository as well as from four private laboratories. Mumps-specific immunoglobulin M (IgM) and/or viral nucleic acid positive results represented acute infections. We used age-specific mid-year population estimates for each study year as denominators when calculating annual cumulative incidence. Seasonality was based on the season that showed a peak in infections. RESULTS: Out of 48,580 records obtained from the public and private sectors, 46,713 (96.2%) were from the private sector. Over the study period, there were 7494 acute infections, 7085 (94.5%) of which were recorded in the private sector. Of these 7494 infections, 3924 (52.4%) occurred in males. The proportion of samples tested that were IgM positive was 18.6% (1058/5682) in 2012, 15% (1016/6790) in 2013, 15.8% (1280/8093) in 2014, 15.5% (1384/8944) in 2015, 13.1% (1260/9629) in 2016 and 15.8% (1496/9442) in 2017. The cumulative incidence rate per 100,000 was highest in children between one and 9 years throughout the study period. The cumulative incidence of infections was highest in the Western Cape, Gauteng and the Northern Cape. Infections peaked in June and November. CONCLUSION: Laboratory-confirmed mumps infections predominantly occurred in spring, affecting children below 10 years of age and individuals who were male. There were fewer tests performed in the public sector compared to the private sector. Since only laboratory data was analysed our results represent and underestimate of disease burden. Further studies that include clinical data are required to provide better estimates of disease burden in South Africa.
format Online
Article
Text
id pubmed-7216493
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72164932020-05-18 Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study Sikhosana, Mpho Lerato Kuonza, Lazarus Motaze, Nkengafac Villyen BMC Public Health Research Article BACKGROUND: Data on the burden of mumps in South Africa are limited and the epidemiology of mumps in this setting is not well understood. We present an analysis of mumps data in South Africa from 2012 to 2017. METHODS: This cross-sectional study included secondary data on laboratory-confirmed mumps infections from 2012 to 2017, archived at the South African National Health Laboratory Services’ data repository as well as from four private laboratories. Mumps-specific immunoglobulin M (IgM) and/or viral nucleic acid positive results represented acute infections. We used age-specific mid-year population estimates for each study year as denominators when calculating annual cumulative incidence. Seasonality was based on the season that showed a peak in infections. RESULTS: Out of 48,580 records obtained from the public and private sectors, 46,713 (96.2%) were from the private sector. Over the study period, there were 7494 acute infections, 7085 (94.5%) of which were recorded in the private sector. Of these 7494 infections, 3924 (52.4%) occurred in males. The proportion of samples tested that were IgM positive was 18.6% (1058/5682) in 2012, 15% (1016/6790) in 2013, 15.8% (1280/8093) in 2014, 15.5% (1384/8944) in 2015, 13.1% (1260/9629) in 2016 and 15.8% (1496/9442) in 2017. The cumulative incidence rate per 100,000 was highest in children between one and 9 years throughout the study period. The cumulative incidence of infections was highest in the Western Cape, Gauteng and the Northern Cape. Infections peaked in June and November. CONCLUSION: Laboratory-confirmed mumps infections predominantly occurred in spring, affecting children below 10 years of age and individuals who were male. There were fewer tests performed in the public sector compared to the private sector. Since only laboratory data was analysed our results represent and underestimate of disease burden. Further studies that include clinical data are required to provide better estimates of disease burden in South Africa. BioMed Central 2020-05-12 /pmc/articles/PMC7216493/ /pubmed/32397991 http://dx.doi.org/10.1186/s12889-020-08835-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Sikhosana, Mpho Lerato
Kuonza, Lazarus
Motaze, Nkengafac Villyen
Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study
title Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study
title_full Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study
title_fullStr Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study
title_full_unstemmed Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study
title_short Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012–2017: a cross-sectional study
title_sort epidemiology of laboratory-confirmed mumps infections in south africa, 2012–2017: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216493/
https://www.ncbi.nlm.nih.gov/pubmed/32397991
http://dx.doi.org/10.1186/s12889-020-08835-x
work_keys_str_mv AT sikhosanampholerato epidemiologyoflaboratoryconfirmedmumpsinfectionsinsouthafrica20122017acrosssectionalstudy
AT kuonzalazarus epidemiologyoflaboratoryconfirmedmumpsinfectionsinsouthafrica20122017acrosssectionalstudy
AT motazenkengafacvillyen epidemiologyoflaboratoryconfirmedmumpsinfectionsinsouthafrica20122017acrosssectionalstudy